Canaccord Genuity Rates ACADIA Pharmaceuticals (ACAD) buy

Canaccord Genuity Sees Upside in ACADIA Pharmaceuticals

On June 29, 2026, analyst Sumant Kulkarni from Canaccord Genuity reaffirmed a positive outlook on ACADIA Pharmaceuticals Inc. ($ACAD). The firm kept its buy rating on the Nasdaq-listed biotechnology company and set a price target of $36.00. This move suggests the analyst believes there is plenty of room for the stock to climb from its current levels. At the time of the report, the stock was trading around $25.50 on Monday, meaning the $36.00 target represents a price point more than 40% above where shares are today.

ACADIA Stock Performance and Valuation

Shares of ACADIA Pharmaceuticals have shown some resilience, though they remain below the highs seen over the past year. The stock has a 52-week range between $19.69 and $30.96. Currently, the price is sitting above its 200-day moving average of $24.63, which is a common technical level investors watch to determine long-term trends. However, it is slightly below its 50-day moving average of $27.61.

With a price-to-earnings (P/E) ratio of 11.8, the market is valuing the company's current profits at a lower multiple than its future growth might suggest, as the forward P/E ratio stands at 29.7. The company maintains a healthy balance sheet with a current ratio of 3.39, which measures its ability to cover short-term obligations with assets like cash.

Double-Digit Revenue Growth at ACADIA

In its most recent financial results, ACADIA Pharmaceuticals reported total revenue of $1.14 billion. This reflects a revenue growth rate of 16.4%, showing the company is expanding its top line at a steady clip. Profitability also looks strong for a biotech firm of this size, with a net margin of 33.4% and a return on equity of 35.7%. These figures suggest the company is efficiently turning its sales into profit and effectively using shareholder investments. Investors are looking forward to the next earnings update, which is scheduled for November 4, 2026.

Mixed Sentiment Among Wall Street Analysts

While Canaccord Genuity is bullish, other firms have adjusted their expectations recently. On October 13, 2026, UBS downgraded the stock from a previous target of $49.00 down to $23.00 with a neutral rating. Conversely, RBC Capital maintained an outperform rating on October 8, 2026, with a $36.00 target. Other firms like Deutsche Bank and Citigroup also maintain buy ratings, though several have lowered their price targets since September 2026. The consensus among 19 analysts remains a buy, with an average price target of $33.89.

Focus on Neurological and Rare Diseases

ACADIA Pharmaceuticals is a San Diego-based biopharmaceutical company that develops treatments for central nervous system disorders. Its primary products include Nuplazid, used for Parkinson's disease psychosis, and Daybue, which treats Rett syndrome. The company's ability to commercialize these specialty drugs while maintaining a pipeline of experimental treatments for Alzheimer's and other rare diseases is the primary driver behind the current analyst interest.

Looking Ahead for ACADIA

The gap between the current share price and the $36.00 target from Canaccord Genuity will be a key point of interest for investors as the year progresses. While the analyst community is generally positive, the wide range of price targets—from a low of $17.00 to a high of $49.00—shows there is still debate over the company's long-term valuation. The upcoming earnings report in November will likely provide more clarity on whether the company can sustain its current growth trajectory.